Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making manufacturing inroads in the U.S. by way of an acquisition.

Samsung Bio’s U.S. subsidiary will pay $280 million to acquire GSK's Human Genome Sciences and its two pharmaceutical manufacturing plants at a campus in Rockville, Maryland. The site, which will mark Samsung Bio’s first for production in the U.S., features a total 60,000 liters of drug substance capacity and is equipped to handle clinical and commercial manufacturing from small to large scale, according to a Dec. 21 press release.

After working as partners, GSK moved in to acquire Human Genome Sciences for approximately $3.6 billion back in 2012.

Samsung Bio says it will continue to manufacture products already being made at the site and noted that it plans to invest further to expand capacity and upgrade technology there “to further support a more resilient U.S. supply chain for critical biologic medicines.”

Samsung Bio also plans to retain “more than 500” employees at the site. The Korean CDMO says that it expects the deal to close toward the end of 2026’s first quarter.

"Today's agreement to divest the Rockville manufacturing site to our valued long-term partner, Samsung Biologics, will secure the manufacture of two important medicines on US soil for US patients and further build GSK's supply chain resilience,” Regis Simard, GSK’s president of global supply chain, said in a statement. Simard did not clarify which drugs Samsung will continue to produce.

By: DocMemory
Copyright © 2023 CST, Inc. All Rights Reserved